Diana M. Negoescu

Diana M. Negoescu

Auto-generated profile, based on publicly available information

Diana M. Negoescu

Department of Industrial and Systems Engineering, University of Minnesota, Minneapolis, Minnesota 55455

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2017 in Management Science
Verified
Journal Article
Closed access
DNDiana M. Negoescu
Diana M. Negoescu
KBKostas Bimpikis
Kostas Bimpikis
MBMargaret L. Brandeau
Margaret L. Brandeau
DIDan A. Iancu
Dan A. Iancu
Currently available medication for treating many chronic diseases is often effective only for a subgroup of patients, and biomarkers accurately assessing whether an individual belongs to this subgroup typically do not exist. In such settings, physicians learn about the effectiveness of a drug primarily through experimentation—i.e., by initiating treatment and monitoring the patient’s response. Precise guidelines for discontinuing treatment are often lacking or left entirely to the physician’s discretion. We introduce a framework for developing adaptive, personalized treatments for such chronic diseases. Our model is based on a continuous-time, multi-armed bandit setting where drug effectiveness is assessed by aggregating information from several channels: by continuously monitoring the state of the patient, but also by (not) observing the occurrence of particular infrequent health events, such as relapses or disease flare-ups. Recognizing that the timing and severity of such events provide critical information for treatment decisions is a key point of departure in our framework compared with typical (bandit) models used in healthcare. We show that the model can be analyzed in closed form for several settings of interest, resulting in optimal policies that are intuitive and may have practical appeal. We illustrate the effectiveness of the methodology by developing a set of efficient treatment policies for multiple sclerosis, which we then use to benchmark several existing treatment guidelines.The online appendix is available at https://doi.org/10.1287/mnsc.2017.2793 .This paper was accepted by Noah Gans, stochastic models and simulation.

1 May 2022 in Operations Research
Verified
Journal Article
Closed access
SSSze-chuan Suen
Sze-chuan Suen
DNDiana Negoescu
Diana Negoescu
JGJoel Goh
Joel Goh
Designing Incentives to Promote Treatment Adherence Premature cessation of antibiotic therapy is common and can severely compromise health outcomes, potentially leading to worsening health, disease transmission, and antibiotic resistance. In “Design of Incentive Programs for Optimal Medication Adherence in the Presence of Observable Consumption,” Sze-chuan Suen, Diana Negoescu, and Joel Goh investigate the problem of designing a schedule of incentive payments to induce socially optimal treatment adherence levels in settings in which treatment adherence can be observed but patient preferences for treatment adherence are heterogeneous and unobservable to a health provider. The novel elements of this problem stem from its institutional features: there is a single incentive schedule applied to all patients, incentive payments must be increasing in patients’ adherence, and patients cannot be a priori prohibited from any given levels of adherence. The authors develop models to design optimal incentives incorporating these features and conduct a numerical study of the tuberculosis epidemic in India.

1 March 2017 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
DNDiana M. Negoescu
Diana M. Negoescu
ZZZhenhuan Zhang
Zhenhuan Zhang
HBHeiner C. Bucher
Heiner C. Bucher
EBEran Bendavid
Eran Bendavid
Viral load (VL) monitoring for patients receiving antiretroviral therapy (ART) is recommended worldwide. However, the costs of frequent monitoring are a barrier to implementation in resource-limited settings. The extent to which personalized monitoring frequencies may be cost-effective is unknown. We created a simulation model parameterized using person-level longitudinal data to assess the benefits of flexible monitoring frequencies. Our data-driven model tracked human immunodeficiency virus (HIV)–infected individuals for 10 years following ART initiation. We optimized the interval between viral load tests as a function of patients’ age, gender, education, duration since ART initiation, adherence behavior, and the cost-effectiveness threshold. We compared the cost-effectiveness of the personalized monitoring strategies to fixed monitoring intervals every 1, 3, 6, 12, and 24 months. Shorter fixed VL monitoring intervals yielded increasing benefits (6.034 to 6.221 discounted quality-adjusted life-years [QALYs] per patient with monitoring every 24 to 1 month over 10 years, respectively, standard error = 0.005 QALY), at increasing average costs: US$3445 (annual monitoring) to US$5393 (monthly monitoring) per patient, respectively (standard error = US$3.7). The adaptive policy optimized for low-income contexts achieved 6.142 average QALYs at a cost of US$3524, similar to the fixed 12-month policy (6.135 QALYs, US$3518). The adaptive policy optimized for middle-income resource settings yields 0.008 fewer QALYs per person, but saves US$204 compared to monitoring every 3 months. The benefits from implementing adaptive vs fixed VL monitoring policies increase with the availability of resources. In low- and middle-income countries, adaptive policies achieve similar outcomes to simpler, fixed-interval policies.

8 January 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AZAnthony Zhenhuan Zhang
Anthony Zhenhuan Zhang
DNDiana Negoescu
Diana Negoescu
Claudia  Munoz-ZanziClaudia Munoz-Zanzi
Claudia Munoz-Zanzi
Febrile illness caused by viral and bacterial diseases (e.g., dengue and leptospirosis) often have similar symptoms and are difficult to differentiate without diagnostic tests. If not treated appropriately, patients may experience serious complications. The question of what diagnostic tests to make available to providers in order to inform antibiotic therapy remains an open problem for health services facing limited resources. We formulated the problem of minimizing the weighted average of antibiotic underuse and overuse to inform the optimal diagnostic test and antibiotic treatment options for given occurrence probabilities of several bacterial and viral infections. We modeled the weight of antibiotic overuse as a monetary penalty per unnecessarily administered course, which we varied in both the base case and sensitivity analysis. Detailed Markov cohort models of febrile illness progression were used to estimate the weight of antibiotic underuse. The model accounted for multiple infections simultaneously and incorporated test, treatment, and other direct and indirect costs, as well as the effect of delays in seeking care and test turnaround times. We used the Markov models to numerically estimate disability-adjusted life years (DALYs), pre-penalty costs, and likelihood of antibiotics overuse per patient for fifteen different strategies in two example settings in Thailand, one with a higher probability of bacterial infections (Northern Thailand, Scenario A) and one with a higher probability of viral infections (Bangkok, Scenario B). We found that empirical antibiotic treatment to all patients always incurs the lowest pre-penalty cost (Scenario A: $47.5/patient, $100.6/patient, $149.5/patient for patients seeking care on day one, day four, and day ten respectively; Scenario B: $94.1/patient, $108.7/patient, $122.1/patient on day one, day four, and day ten respectively), and the lowest DALYs, (Scenario A: 0.2 DALYs/patient, 0.9 DALYs/patient, 1.7 DALYs/patient on day one, day four, and day ten, respectively; Scenario B: 0.5 DALYs/patient, 0.7 DALYs/patient, 0.9 DALYs/patient on day one, day four, and day ten, respectively). However, such strategy resulted in the highest proportion of antibiotic overuse per patient (Scenario A: 38.1%, 19.3%, 7.5% on day one, day four, and day ten, respectively; Scenario B: 82.9%, 42.1%, 16.3% on day one, day four, and day ten, respectively). Consequently, empirical antibiotic treatment became suboptimal with antibiotic overuse penalties above $12,800/course, $18,400/course, $23,900/course for patients presenting on day one, day four, and day ten in Scenario A and above $1,100/course, $1,500/course, $1,600/course for patients presenting on day one, day four, and day ten in Scenario B. Empirical antibiotic treatment to all patients provided the best outcomes if antibiotic overuse was not the primary concern or if presenting with viral disease (such as dengue) was unlikely. Empirical antibiotic treatment to severe patients only was in most cases not beneficial. Otherwise, strategies involving diagnostic tests became optimal. In particular, our results indicated that single test strategies (bacterial RDT or viral PCR) were optimal in regions with a greater probability of presenting with viral infection. PCR-led strategies (e.g., parallel bacterial PCR, or multiplex PCR) are robust under parameter uncertainty (e.g., with uncertain disease occurrence probabilities).